Hormonal
Peripheral administration of PYY3-36 reduces food intake and 24-hour caloric intake in both normal-weight and obese humans.
Your body naturally releases PYY after eating to signal fullness. In obesity, this signal is often weaker. Research shows that replacing or boosting this hormone can effectively reduce appetite and calorie intake, even in obese individuals, suggesting that targeting this pathway is a viable strategy for weight management.
peripheral infusion of PYY3-36 reduced appetite and 24 h caloric intake (Batterham et al. 2002)... obese subjects remained sensitive to the anorectic actions of PYY3-36 (Batterham et al. 2003).
Why this rating
Multiple human studies (Batterham 2002, 2003, le Roux 2006) and rodent studies are cited showing consistent anorectic effects.
Source
The role of peptide YY in appetite regulation and obesity
Efthimia Karra et al. · The Journal of Physiology · 2008
DOI 10.1113/jphysiol.2008.164269
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →